152 related articles for article (PubMed ID: 25591119)
21. Activity and substrate specificity of the murine STK2 Serine/Threonine kinase that is structurally related to the mitotic regulator protein NIMA of Aspergillus nidulans.
Hayashi K; Igarashi H; Ogawa M; Sakaguchi N
Biochem Biophys Res Commun; 1999 Oct; 264(2):449-56. PubMed ID: 10529384
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
23. An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9.
Richards MW; O'Regan L; Mas-Droux C; Blot JM; Cheung J; Hoelder S; Fry AM; Bayliss R
Mol Cell; 2009 Nov; 36(4):560-70. PubMed ID: 19941817
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
[TBL] [Abstract][Full Text] [Related]
25. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
28. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N
Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive substrate specificity profiling of the human Nek kinome reveals unexpected signaling outputs.
van de Kooij B; Creixell P; van Vlimmeren A; Joughin BA; Miller CJ; Haider N; Simpson CD; Linding R; Stambolic V; Turk BE; Yaffe MB
Elife; 2019 May; 8():. PubMed ID: 31124786
[TBL] [Abstract][Full Text] [Related]
30. Aminopyrimidinone cdc7 kinase inhibitors.
Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD
Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396
[TBL] [Abstract][Full Text] [Related]
31. A NIMA-related protein kinase suppresses ectopic outgrowth of epidermal cells through its kinase activity and the association with microtubules.
Motose H; Tominaga R; Wada T; Sugiyama M; Watanabe Y
Plant J; 2008 Jun; 54(5):829-44. PubMed ID: 18266916
[TBL] [Abstract][Full Text] [Related]
32. Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.
Platzer C; Najjar A; Rohe A; Erdmann F; Sippl W; Schmidt M
Bioorg Med Chem; 2018 Aug; 26(14):4014-4024. PubMed ID: 29941193
[TBL] [Abstract][Full Text] [Related]
33. Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors.
Liu M; Huang J; Chen DX; Jiang C
Bioorg Med Chem Lett; 2015 Feb; 25(3):431-4. PubMed ID: 25556101
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
Keppner S; Proschak E; Schneider G; Spänkuch B
ChemMedChem; 2009 Nov; 4(11):1806-9. PubMed ID: 19746360
[No Abstract] [Full Text] [Related]
35. Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.
Han M; Sun D
J Comput Aided Mol Des; 2019 Jul; 33(7):689-698. PubMed ID: 31203490
[TBL] [Abstract][Full Text] [Related]
36. Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads.
Spänkuch B; Keppner S; Lange L; Rodrigues T; Zettl H; Koch CP; Reutlinger M; Hartenfeller M; Schneider P; Schneider G
Angew Chem Int Ed Engl; 2013 Apr; 52(17):4676-81. PubMed ID: 23166089
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
Shaik A; Bhakuni R; Kirubakaran S
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
[TBL] [Abstract][Full Text] [Related]
38. Caught Nek-ing: cilia and centrioles.
Quarmby LM; Mahjoub MR
J Cell Sci; 2005 Nov; 118(Pt 22):5161-9. PubMed ID: 16280549
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
40. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
